We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
Read MoreHide Full Article
Regulus Therapeutics Inc. (RGLS - Free Report) announced that the FDA has accepted the investigational new drug (“IND”) application for its novel pipeline candidate, RGLS8429, seeking approval to begin clinical studies on the same for the treatment of autosomal dominant polycystic kidney disease (“ADPKD”).
The company plans to initiate a phase I study evaluating RGLS8529 in healthy volunteers for treating ADPKD later in the second quarter of 2022.
Shares of Regulus were up 54.8% following the announcement of the news on Wednesday. The stock has lost 15.6% so far this year compared with the industry’s decline of 26.8%.
Image Source: Zacks Investment Research
A phase I single-ascending dose study will assess the safety, tolerability and pharmacokinetics of RGLS8429 in healthy volunteers. After this study, Regulus intends to begin a phase Ib multiple-ascending dose study in adult patients with ADPKD.
The company plans to report data from the healthy volunteer study and start dosing patients with ADPKD during the second half of 2022.
Per the press release, in the United States, around 140,000 individuals are diagnosed with ADPKD, with an estimated four to seven million affected worldwide. Hence if successfully developed and upon potential approval, RGLS8429 may offer a transformative treatment option for the given patient population.
Apart from RGLS8429, Regulus is developing another pipeline candidate, lademirsen (RG-012), for the treatment of adult patients with Alport syndrome, an inherited form of kidney disease.
The company, under its collaboration with French pharma giant, Sanofi (SNY - Free Report) , announced the completion of enrollment in the phase II HERA study evaluating lademirsen for treating Alport syndrome in February 2022.
In November 2018, Regulus transitioned development responsibilities for RG-012 to Genzyme, a subsidiary of Sanofi. SNY bears all costs for the development of lademirsen.
RGLS currently has no approved product in its portfolio. Therefore, the successful development of its pipeline candidates remains in key focus for the company.
Onconova Therapeutics’ loss per share estimates have narrowed 22.4% for 2022 and 18.2% for 2023 over the past 60 days.
Earnings of Onconova Therapeutics have surpassed estimates in each of the trailing three quarters. ONTX delivered an earnings surprise of 22.72% on average.
Soleno Therapeutics’ loss per share estimates have narrowed 9.1% for 2022 and 25.9% for 2023 over the past 60 days.
Earnings of Soleno Therapeutics have surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion. SLNO delivered an earnings surprise of -10.92%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
Regulus Therapeutics Inc. (RGLS - Free Report) announced that the FDA has accepted the investigational new drug (“IND”) application for its novel pipeline candidate, RGLS8429, seeking approval to begin clinical studies on the same for the treatment of autosomal dominant polycystic kidney disease (“ADPKD”).
The company plans to initiate a phase I study evaluating RGLS8529 in healthy volunteers for treating ADPKD later in the second quarter of 2022.
Shares of Regulus were up 54.8% following the announcement of the news on Wednesday. The stock has lost 15.6% so far this year compared with the industry’s decline of 26.8%.
Image Source: Zacks Investment Research
A phase I single-ascending dose study will assess the safety, tolerability and pharmacokinetics of RGLS8429 in healthy volunteers. After this study, Regulus intends to begin a phase Ib multiple-ascending dose study in adult patients with ADPKD.
The company plans to report data from the healthy volunteer study and start dosing patients with ADPKD during the second half of 2022.
Per the press release, in the United States, around 140,000 individuals are diagnosed with ADPKD, with an estimated four to seven million affected worldwide. Hence if successfully developed and upon potential approval, RGLS8429 may offer a transformative treatment option for the given patient population.
Apart from RGLS8429, Regulus is developing another pipeline candidate, lademirsen (RG-012), for the treatment of adult patients with Alport syndrome, an inherited form of kidney disease.
The company, under its collaboration with French pharma giant, Sanofi (SNY - Free Report) , announced the completion of enrollment in the phase II HERA study evaluating lademirsen for treating Alport syndrome in February 2022.
In November 2018, Regulus transitioned development responsibilities for RG-012 to Genzyme, a subsidiary of Sanofi. SNY bears all costs for the development of lademirsen.
RGLS currently has no approved product in its portfolio. Therefore, the successful development of its pipeline candidates remains in key focus for the company.
Zacks Rank & Other Stocks to Consider
Regulus currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the same sector include Onconova Therapeutics, Inc. and Soleno Therapeutics, Inc. (SLNO - Free Report) , both carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Onconova Therapeutics’ loss per share estimates have narrowed 22.4% for 2022 and 18.2% for 2023 over the past 60 days.
Earnings of Onconova Therapeutics have surpassed estimates in each of the trailing three quarters. ONTX delivered an earnings surprise of 22.72% on average.
Soleno Therapeutics’ loss per share estimates have narrowed 9.1% for 2022 and 25.9% for 2023 over the past 60 days.
Earnings of Soleno Therapeutics have surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion. SLNO delivered an earnings surprise of -10.92%, on average.